Skip to main content

XTL Biopharmaceuticals Ltd

XTLB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001023549

No open-market purchases or sales by XTL Biopharmaceuticals Ltd insiders were filed in the last 90 days; 3 institutions reported holding it in 13F filings for Q2 2026, worth $20.7K in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding XTL Biopharmaceuticals Ltd changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of XTLB: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders56+1
Shares500.7K487.4K−13.3K (−2.7%)
Value$2.00M$2.13M+$136.0K (+6.8%)

New holders (2)

Institutions that held XTL Biopharmaceuticals Ltd at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to XTLB in Q3 2021
InstitutionSharesValue% of portfolio
Citadel Advisors LLC12,801$56.0K0.00%
UBS Group AG2,898$13.0K0.00%

Sold out (1)

Institutions that held XTL Biopharmaceuticals Ltd at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of XTLB in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Steel Peak Wealth Management LLC11,671$47.0K